Clinical trial designs for evaluating the medical utility of prognostic and predictive biomarkers in oncology.
about
Biomarker-Guided Adaptive Trial Designs in Phase II and Phase III: A Methodological ReviewStatistical Methods for Establishing Personalized Treatment Rules in OncologyStrategies for dealing with missing data in clinical trials: from design to analysisComparison of CATs, CURB-65 and PMEWS as triage tools in pandemic influenza admissions to UK hospitals: case control analysis using retrospective dataStrategies for power calculations in predictive biomarker studies in survival dataCompanion diagnostics for targeted cancer drugs - clinical and regulatory aspectsMulticenter trials using ¹⁸F-fluorodeoxyglucose (FDG) PET to predict chemotherapy response: effects of differential measurement error and bias on power calculations for unselected and enrichment designs.Evaluation of a chemoresponse assay as a predictive marker in the treatment of recurrent ovarian cancer: further analysis of a prospective studyClinical trial designs for testing biomarker-based personalized therapies.Deep sequencing of gastric carcinoma reveals somatic mutations relevant to personalized medicine.Innovative Clinical Trial Designs: Toward a 21st-Century Health Care SystemTreatment of Metastatic Breast Cancer in a Real-World Scenario: Is Progression-Free Survival With First Line Predictive of Benefit From Second and Later Lines?Moving from correlative science to predictive oncology.Promise and pitfalls of quantitative imaging in oncology clinical trials.NCI-RTOG translational program strategic guidelines for the early-stage development of radiosensitizers.Minimal Residual Disease Evaluation in Childhood Acute Lymphoblastic Leukemia: A Clinical Evidence Review.Genomic biomarkers for personalized medicine: development and validation in clinical studiesPersonalized medicine and oncology practice guidelines: a case study of contemporary biomarkers in colorectal cancer.Biomarker use in colorectal cancer therapy.Subgroup-Based Adaptive (SUBA) Designs for Multi-Arm Biomarker Trials.Bayesian Two-stage Biomarker-based Adaptive Design for Targeted Therapy Development.Adaptive designs for clinical trials assessing biomarker-guided treatment strategies.Biomarker-Guided Non-Adaptive Trial Designs in Phase II and Phase III: A Methodological Review.Personalized medicine in oncology: tailoring the right drug to the right patient.Integrating biomarkers in clinical trials.Systems biology technologies enable personalized traditional Chinese medicine: a systematic review.Implementing personalized cancer genomics in clinical trials.Pharmacogenomic biomarkers for personalized medicine.Personalizing oncology treatments by predicting drug efficacy, side-effects, and improved therapy: mathematics, statistics, and their integration.Drug-diagnostic co-development: challenges and issues.Beyond Correlations, Sensitivities, and Specificities: Case Examples of the Evaluation of Advanced Imaging in Oncology Clinical Trials and Cancer Treatment.Beyond Correlations, Sensitivities, and Specificities: A Roadmap for Demonstrating Utility of Advanced Imaging in Oncology Treatment and Clinical Trial Design.Combining Prognostic and Predictive Enrichment Strategies to Identify Children With Septic Shock Responsive to Corticosteroids.Exploitation of Gene Expression and Cancer Biomarkers in Paving the Path to Era of Personalized Medicine.Comparing diagnostic tests on benefit-risk.Transparency of reporting in molecular diagnostics.Patient-derived xenografts effectively capture responses to oncology therapy in a heterogeneous cohort of patients with solid tumors.Generating and evaluating evidence of the clinical utility of molecular diagnostic tests in oncology.Evolution of Chemosensitivity and Resistance Assays as Predictors of Clinical Outcomes in Epithelial Ovarian Cancer Patients.An Enrichment Strategy For Sepsis Clinical Trials.
P2860
Q26766584-C06C53DA-B68F-4726-B917-CBD625E056E6Q26786366-D263D6DB-9A07-476F-B849-04F80C53E414Q26999795-A6F73E3B-EBFF-460F-838D-81EC0C96BFE2Q28730789-D585B149-E5D7-4AD9-9EA9-78979831F493Q31132692-FDBF3DE4-5F2E-4A69-A680-DAF06A67BF4FQ33657876-2A6EDFE7-DB0D-444D-B5A2-066EB065B392Q33921056-8215B8D3-CD86-43D7-AE77-4DDC875E0850Q34113564-17E5CDC5-F141-4852-B605-03FAA16434D5Q34977663-192B656D-0AFE-40D9-B254-5B23FF908766Q35153864-5F4DA3F8-DE68-4689-A613-CA164B529E00Q35797280-5DE72FD2-F0AA-475A-8EC6-090221547963Q35820575-FAB5B0B6-F7A9-4F97-B5A7-0847BA69191EQ36117650-6D0EA462-ACEF-495E-A68D-6A44C6021096Q36303765-AE9864A3-F164-4FC2-8A81-3D36D763BB88Q36507559-C8473586-4B3C-4D4B-B537-9DE960937FC1Q36731636-2D356D39-E4BE-44DF-B19E-5E23D4D1087DQ36837848-D2353CEE-A2EC-43BE-862B-FDDC54C6BE31Q36964450-8FB932E4-98B8-4E52-8926-81A5EFA0B734Q36968539-1E3FC64E-C858-43BC-B799-85C1AA44DD30Q37238712-08E2F728-5BBE-4490-8384-74D90BBA30F7Q37238720-BDEDEA35-A7E3-4658-A61D-EED9FD3648E2Q37711677-9D58887C-E5C8-4749-B061-6C0F9107A30AQ37731264-5B25EF83-13CE-43FE-BD61-445434E44818Q37779306-9F54FEF4-FE25-44F7-93B9-38599C9C595EQ37853183-171F5970-9590-4578-82AF-35EAAED4237BQ38066235-AF0A51DE-2B85-4BFB-B009-7DAEA025BE50Q38102920-C9A38F2B-89F4-4338-9185-146B326CDAB9Q38112822-E998AB5A-E881-42C7-B213-85792295DE05Q38194107-FE5ADD8D-7CD1-42F6-8813-74AB26851D51Q38664437-93B54785-A236-4509-BB13-BAB4A488BC46Q38836364-2A9A6E13-890A-4AE7-9FB9-2711DC9C55DDQ39272347-C4054DF7-D9BC-4E51-A5EC-9FB06358645FQ40642645-204C2E29-8092-4FE6-8B1C-18FF6D5F3B60Q41603225-CC2D583B-10DA-41EB-979B-3C50BD894D92Q41811354-BA71AFFC-D8DA-45E2-8EC9-449890F2C8CEQ42580605-18B7446B-01F4-4E87-93E1-9B431F78C70FQ45068320-0D3F5D67-5544-402E-A3A9-472EFA1B2AF4Q46062336-15E2DF33-6F4F-4A22-91C0-DA8F0101BB7BQ47965726-4E2A09C7-457E-4019-A149-376A05F5B5F2Q49160004-CEE5BDAB-6D73-4CF6-9C08-5AAFAC229D53
P2860
Clinical trial designs for evaluating the medical utility of prognostic and predictive biomarkers in oncology.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Clinical trial designs for eva ...... ictive biomarkers in oncology.
@ast
Clinical trial designs for eva ...... ictive biomarkers in oncology.
@en
type
label
Clinical trial designs for eva ...... ictive biomarkers in oncology.
@ast
Clinical trial designs for eva ...... ictive biomarkers in oncology.
@en
prefLabel
Clinical trial designs for eva ...... ictive biomarkers in oncology.
@ast
Clinical trial designs for eva ...... ictive biomarkers in oncology.
@en
P2860
P356
P1476
Clinical trial designs for eva ...... ictive biomarkers in oncology.
@en
P2093
Richard Simon
P2860
P356
10.2217/PME.09.49
P407
P577
2010-01-01T00:00:00Z